Skip to Main Content

The Food and Drug Administration on Monday rejected Akcea Therapeutics’ application to market Waylivra, its drug for familial chylomicronemia syndrome, in the United States.

Akcea didn’t give a reason for the rejection. Waylivra, also known as volanesorsen, would have been Akcea’s first drug in the U.S. market. The condition it treats, FCS, leads to a buildup of fat in organs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!